COVID-19 Vax in MS: Lower Response on Certain Medications

New data on COVID vaccination in multiple sclerosis (MS) patients has shown a reduced humoral response in patients treated with the anti-CD20 antibodies ocrelizumab or rituximab, but not in those receiving the similar product, ofatumumab.

The results also show a reduced response to COVID vaccination in some patients on fingolimod.

The data come from a new series of vaccinated MS patients from Madrid, Spain, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress being held virtually October 13-15.